Diclofenac/misoprostol. Pharmacoeconomic implications of therapy.

Author: LambH M, PloskerG L

Paper Details 
Original Abstract of the Article :
The combined formulation of diclofenac/misoprostol provides effective relief of pain and inflammation, with a 2- to 3-fold lower incidence of NSAID-associated gastroduodenal ulcers than diclofenac monotherapy. Both components of the combined formulation have been widely used and have well documented...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.2165/00019053-199916010-00008

データ提供:米国国立医学図書館(NLM)

Diclofenac/Misoprostol: A Cost-Effective Approach to Pain Relief

This study examines the pharmacoeconomic implications of diclofenac/misoprostol, a combined formulation for pain relief. It's like exploring a desert with various pathways – each pathway (treatment option) has its own cost and benefits, and finding the most cost-effective and efficient route (treatment) is essential for optimal results. The researchers compared the cost-effectiveness of diclofenac/misoprostol with other NSAID treatments, taking into account both clinical efficacy and economic factors.

Cost-Effectiveness of Combined Therapy

The study found that diclofenac/misoprostol is associated with similar or lower total direct medical treatment costs compared to other NSAIDs. It's like finding a shortcut through the desert – this combined therapy offers a more efficient and cost-effective way to reach the destination (pain relief) without compromising on safety or efficacy.

Optimal Use in High-Risk Patients

The researchers suggest that diclofenac/misoprostol is particularly beneficial for patients at high risk of developing NSAID-associated gastroduodenal ulcers. It's like navigating a treacherous desert with a reliable guide – this combination therapy offers added protection for those most vulnerable to complications.

Dr.Camel's Conclusion

This study underscores the value of pharmacoeconomic analyses in healthcare decision-making. By considering both clinical efficacy and economic factors, we can identify the most cost-effective treatment options, ensuring access to quality care without unnecessary financial strain.

Date :
  1. Date Completed 1999-08-31
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

10539124

DOI: Digital Object Identifier

10.2165/00019053-199916010-00008

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.